Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 5Multiple Myeloma 4Melanoma 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune-related Adverse Events 1Hematologic Neoplasms 1Glioblastoma 1Craniopharyngioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1Astrocytoma 1

Interventions

tocilizumab 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Immune-related Adverse Events × tocilizumab × Clear all
NCT04375228 2026-02-06

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Columbia University

Phase 2 Active not recruiting
8 enrolled
Other solid neoplasm

Immune-related Adverse Events

Data powered by HemOnc (CC BY 4.0) Colophon âš¡